Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data into Patient Care


Release Date: May 31, 2019
Expiration Date: May 31, 2020
Media: Internet - based

Activity Overview

Community Practice Connections™: Molecular Tumor Board in EGFR Mutation–Positive Lung Cancers: Integrating Clinical Data into Patient Care provides case-based discussion of clinical data guiding therapy for patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene. Clinical scenarios include first-line therapy, molecular testing and managing disease progression on first- and third-generation agents, and managing patients with central nervous system (CNS) metastases. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with lung cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by health care professionals engaged in the care of patients with EGFR mutation-positive NSCLC.

Benefits of Participating

  • Gain insights into the use of liquid-based and tissue-based testing methods to choose the best therapy in patients with EGFR mutation-positive NSCLC
  • Learn about the latest clinical data on first-line treatment of patients with NSCLC and EGFR mutations
  • Expand knowledge of approaches to manage patients whose disease progresses on EGFR inhibitor therapy
  • Develop strategies to manage patients with EGFR mutation-positive NSCLC and CNS metastases

CME Activity Table of Contents

  • Module 1. Initial Therapy for EGFR Mutation-Positive NSCLC
  • Module 2. A Patient Progressing on a First-Line EGFR Inhibitor
  • Module 3. A Patient With CNS Progression

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward medical oncologists and cancer researchers. Other healthcare professionals involved in the study or treatment of lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Evaluate liquid biopsies and other molecular testing approaches to optimize selection in the first-line setting and subsequent lines of therapy for patients with advanced NSCLC
  • Describe key clinical data informing initial treatment of patients with EGFR mutation-positive NSCLC
  • Assess clinical data regarding the management of acquired resistance and disease progression in patients with EGFR mutation-positive NSCLC
  • Discuss interventions for patients with EGFR mutation-positive NSCLC and CNS metastases and/or treatment-related adverse events

Faculty, Staff, and Planners’ Disclosures

David R. Gandara
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant Research Support: Genentech; Consultant: AstraZeneca, Genentech, Boehringer Ingelheim.

Christine M. Lovly
Christine M. Lovly, MD, PhD
Associate Professor of Medicine, Division of Hematology-Oncology
Co-Leader, Translational Research and Interventional Oncology Program
Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Grant Research Support: AstraZeneca, Novartis, Xcovery; Consultant: Novartis, Pfizer, Ariad Pharmaceuticals, Genoptix, AstraZeneca, Takeda, Foundation, Medicine, Sequenom, Clovis Oncology.

Suresh S. Ramalingam
Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, GA

Disclosures: Grant Research Support: Amgen, AbbVie, Bristol-Myers Squibb, Celgene, Lilly, Genentech, Merck, AstraZeneca, Takeda, Loxo Oncology; Consultant: Nektar, Novartis, Pfizer.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By